The New Frontiers in Pharmaceutical Drug Substance and Drug Product CMC for Novel Modalities

We are very excited to announce the PD2M Conference on the New Frontiers in Pharmaceutical DS/SP CMC for Novel Modalities.

This conference aims to connect academia, industry, and government representatives and discuss the current approaches and future directions to process and product development, and manufacturing of biopharmaceuticals different than traditional small molecule and antibody/protein CMC (peptides, oligonucleotides, ADCs, cell/gene therapy, multi-specifics).

Current engineering challenges in DS and DP, state-of-the-art approaches, discussion of successes and failures, control strategy, and regulatory perspective for the new modalities in the biopharmaceutical industry are in scope.​

The conference will include keynote speakers and technical sessions.​

Scientists and chemical engineers, managers, and business professionals and academics in discovery, development, and manufacturing are invited to participate.​​